Legal Status Overview
Gray AreaPeptides in Hawaii are not legal or illegal as a single category; instead, Hawaii has no state statute, administrative rule, or Board of Pharmacy bulletin naming peptides or 'research chemicals' as a distinct class, so the federal FDA framework and general state pharmacy/compounding law control. Under that federal framework, some peptides (e.g., sermorelin) are FDA-approved and available by prescription through compounding pharmacies, while others (e.g., BPC-157) are unapproved research chemicals whose compounding status has shifted back and forth under FDA's 503A bulk-substances review process. Hawaii's Board of Pharmacy has not issued peptide-specific bulletins or enforcement actions that were identified in this research, meaning compliance in practice tracks whatever the FDA currently says about a given compound nationwide.
Key Points
- Hawaii has no identified state statute, administrative code section, or Board of Pharmacy rule that names peptides or 'research chemicals' as a distinct legal category, leaving the subject governed by general pharmacy and federal compounding law rather than a peptide-specific state rule. (No reliable source found for this point — flagged as unverified rather than stated as fact.)
- BPC-157 was placed into Category 2 of the FDA's 503A bulk drug substances list in September 2023, a designation signaling a significant safety concern that restricted its use in compounding pharmacies nationwide, including Hawaii. [1]
- As of April 23, 2026, BPC-157 was removed from the FDA's Category 2 list, meaning the significant-safety-concern designation no longer applies, though the FDA's Pharmacy Compounding Advisory Committee is scheduled to formally review BPC-157 for inclusion on the 503A bulks list on July 23, 2026. [1]
- Sermorelin, by contrast, is a peptide with FDA approval history (as the discontinued brand Geref for pediatric growth hormone deficiency) that is not a controlled substance and remains legally available in Hawaii through licensed compounding pharmacies with a physician's prescription. [2]
- No Hawaii-specific guidance was found addressing whether a person may personally bring or purchase peptides such as BPC-157, TB-500, or HGH while in Hawaii; absent a prescription, FDA's general unapproved-new-drug and personal-importation policies would apply rather than any Hawaii-specific travel rule. (No reliable source found for this point — flagged as unverified rather than stated as fact.)
- No Hawaii Board of Pharmacy bulletin or enforcement action specifically targeting compounded peptide or GLP-1 products (e.g., compounded semaglutide/tirzepatide or BPC-157) was located in this research, so it cannot be confirmed whether Hawaii has taken any state-level enforcement steps beyond the federal 503A/503B framework. (No reliable source found for this point — flagged as unverified rather than stated as fact.)
- No Hawaii-specific telehealth rule addressing prescribing of peptides or GLP-1-class drugs was identified, so prescribing in Hawaii would follow Hawaii's general telehealth and prescribing statutes for licensed practitioners rather than a peptide-specific rule. (No reliable source found for this point — flagged as unverified rather than stated as fact.)
Peptide-by-peptide status in Hawaii
| BPC-157 | BPC-157 is not separately banned under any Hawaii-specific law but is an unapproved research peptide whose compounding status follows the FDA's shifting federal 503A bulk-substances review, having been restricted under Category 2 from September 2023 until its removal from that category on April 23, 2026. [1] |
|---|---|
| Semaglutide / Tirzepatide (GLP-1 class) | No Hawaii-specific rule on compounded semaglutide or tirzepatide was found in this research, so in Hawaii as elsewhere these GLP-1 peptides are legal only in their FDA-approved brand forms (e.g., Ozempic, Wegovy, Mounjaro, Zepbound) by prescription, while compounded versions are governed by the general federal 503A/503B compounding framework rather than any Hawaii-specific statute. |
| TB-500 | No Hawaii-specific statute or Board of Pharmacy rule addressing TB-500 was identified in this research, so its status in Hawaii cannot be confirmed beyond the general federal position that it is an unapproved research peptide not cleared by the FDA for human use. |
| HGH / Somatropin | No Hawaii-specific statute on human growth hormone was identified in this research, so its legal status in Hawaii rests on the general federal rule restricting distribution of human growth hormone to FDA-approved, prescription uses rather than any Hawaii-specific provision. |
Sources
Last researched: 2026-10-02
Frequently asked questions
Can I buy peptides in Hawaii without a prescription?
Buying FDA-approved peptide drugs without a prescription is not lawful in Hawaii, since compounds like sermorelin or GLP-1 medications require a physician's prescription through a licensed pharmacy; unapproved research peptides sold without a prescription fall outside any approved legal pathway and exist in a federal gray zone that Hawaii has not separately regulated. [2]
Is BPC-157 legal in Hawaii?
BPC-157 is not illegal to possess under any Hawaii-specific law identified in this research, but it is an unapproved research peptide whose compounding availability has swung between FDA restriction (Category 2, from September 2023) and removal from that restriction (April 23, 2026), with a formal FDA compounding-list review still pending as of mid-2026. [1]
Can I get semaglutide or tirzepatide peptides through telehealth in Hawaii?
No Hawaii-specific telehealth rule for peptide or GLP-1 prescribing was identified in this research, so any telehealth prescription in Hawaii would need to come from a practitioner licensed under Hawaii's general telehealth and prescribing statutes, using an FDA-approved or properly compounded product rather than an unregulated research-chemical version.
What are the penalties for buying unapproved research peptides in Hawaii?
No Hawaii-specific penalty schedule or enforcement action for unapproved research peptides was identified in this research, so any consequences would likely arise under general federal unapproved-drug enforcement or Hawaii's general pharmacy/consumer-protection statutes rather than a peptide-specific state penalty.
Can I travel to Hawaii with BPC-157, TB-500, or HGH for personal use?
No Hawaii-specific travel or personal-importation rule for these peptides was identified in this research, so travelers would be subject to general FDA personal-use and prescription-drug import policy rather than any rule unique to Hawaii.